Advertisement

The Clinical Significance of Lymph-Node Metastasis

Chapter
  • 511 Downloads
Part of the Cancer Metastasis – Biology and Treatment book series (CMBT, volume 13)

Abstract

Lymph nodes are the initial site of metastasis in many cancers. For patients with clinically localized tumors, the pathologic status of regional nodes is the most important prognostic variable, and techniques to evaluate these nodes radiographically and surgically are critical components in management. Advances in nodal evaluation, particularly sentinel node biopsy, have enabled more accurate nodal evaluation with less morbidity. The therapeutic impact of lymph node dissection remains a subject of controversy in several solid tumors, but growing evidence suggests that early removal of microscopically involved lymph nodes improves the long-term outcome of patients. Nodal metastasis should remain a central focus of clinical research to build on these recent discoveries.

Key words

Lymph nodes metastases Prognosis Lymph node staging Lymph node imaging Lymph node dissection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    de Freitas R, Jr., Costa MV, Schneider SV, et al. Accuracy of ultrasound and clinical examination in the diagnosis of axillary lymph node metastases in breast cancer. Eur J Surg Oncol 1991, 17: 240–4.PubMedGoogle Scholar
  2. 2.
    Kebudi A, Caliskan C, Yetkin G, et al. The role of pre-operative B mode ultrasound in the evaluation of the axillary lymph node metastases in the initial staging of breast carcinoma. Acta Chir Belg 2005, 105: 511–4.PubMedGoogle Scholar
  3. 3.
    Saiag P, Bernard M, Beauchet A, et al. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol 2005, 141: 183–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Starritt EC, Uren RF, Scolyer RA, et al. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cuaneous melanoma. Ann Surg Oncol 2005, 12: 18–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Atula TS, Varpula MJ, Kurki TJ, et al. Assessment of cervical lymph node status in head and neck cancer patients: palpation, computed tomography and low field magnetic resonance imaging compared with ultrasound-guided fine-needle aspiration cytology. Eur J Radiol 1997, 25: 152–61.PubMedCrossRefGoogle Scholar
  6. 6.
    van den Brekel MW, Pameijer FA, Koops W, et al. Computed tomography for the detection of neck node metastases in melanoma patients. Eur J Surg Oncol 1998, 24: 51–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Lanng C, Hoffmann J, Galatius H, Engel U. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. Eur J Surg Oncol 2007, 33: 281–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Mathijssen IM, Strijdhorst H, Kiestra SK, Wereldsma JC. Added value of ultrasound in screening the clinically negative axilla in breast cancer. J Surg Oncol 2006, 94: 364–7.PubMedCrossRefGoogle Scholar
  9. 9.
    van Rijk MC, Deurloo EE, Nieweg OE, et al. Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol 2006, 13: 31–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Brancato B, Zappa M, Bricolo D, et al. Role of ultrasound-guided fine needle cytology of axillary lymph nodes in breast carcinoma staging. Radiol Med (Torino) 2004, 108: 345–55.Google Scholar
  11. 11.
    Kuenen-Boumeester V, Menke-Pluymers M, de Kanter AY, et al. Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure. Eur J Cancer 2003, 39: 170–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Gilissen F, Oostenbroek R, Storm R, et al. Prevention of futile sentinel node procedures in breast cancer: ultrasonography of the axilla and fine-needle aspiration cytology are obligatory. Eur J Surg Oncol 2008, 34: 497–500.PubMedGoogle Scholar
  13. 13.
    Nathanson SD, Burke M, Slater R, Kapke A. Preoperative identification of the sentinel lymph node in breast cancer. Ann Surg Oncol 2007, 14: 3102–10.PubMedCrossRefGoogle Scholar
  14. 14.
    de Kanter AY, van Eijck CH, van Geel AN, et al. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg 1999, 86: 1459–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Sato K, Tamaki K, Tsuda H, et al. Utility of axillary ultrasound examination to select breast cancer patients suited for optimal sentinel node biopsy. Am J Surg 2004, 187: 679–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Avril N, Adler LP. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. Radiol Clin North Am 2007, 45: 645–57, vi.PubMedCrossRefGoogle Scholar
  17. 17.
    Mustafa S, Marshall C, Griffiths PA, et al. 18F-FDG dual-headed gamma camera PET in detection of axillary nodal disease in patients with large or locally advanced breast cancer: Possible alternative staging of axilla. Oncol Rep 2007, 18: 1545–9.PubMedGoogle Scholar
  18. 18.
    Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004, 22: 277–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Pamilo M, Soiva M, Lavast EM. Real-time ultrasound, axillary mammography, and clinical examination in the detection of axillary lymph node metastases in breast cancer patients. J Ultrasound Med 1989, 8: 115–20.PubMedGoogle Scholar
  20. 20.
    Bafounta ML, Beauchet A, Chagnon S, Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol 2004, 5: 673–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Brountzos EN, Panagiotou IE, Bafaloukos DI, Kelekis DA. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma. Oncol Rep 2003, 10: 505–10.PubMedGoogle Scholar
  22. 22.
    Ulrich J, Voit C. Ultrasound in dermatology. Part II. Ultrasound of regional lymph node basins and subcutaneous tumours. Eur J Dermatol 2001, 11: 73–9.PubMedGoogle Scholar
  23. 23.
    Voit C, Kron M, Schafer G, et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 2006, 13: 1682–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Voit C, Mayer T, Kron M, et al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer 2001, 91: 2409–16.PubMedCrossRefGoogle Scholar
  25. 25.
    Machet L, Nemeth-Normand F, Giraudeau B, et al. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. Br J Dermatol 2005, 152: 66–70.PubMedCrossRefGoogle Scholar
  26. 26.
    van Rijk MC, Teertstra HJ, Peterse JL, et al. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol 2006, 13: 1511–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Sibon C, Chagnon S, Tchakerian A, et al. The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. Melanoma Res 2007, 17: 233–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Hocevar M, Bracko M, Pogacnik A, et al. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res 2004, 14: 533–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Rossi CR, Mocellin S, Scagnet B, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 2003, 83: 80–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Testori A, Lazzaro G, Baldini F, et al. The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Res 2005, 15: 191–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Dalle S, Paulin C, Lapras V, et al. Fine-needle aspiration biopsy with ultrasound guidance in patients with malignant melanoma and palpable lymph nodes. Br J Dermatol 2006, 155: 552–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Haberal I, Celik H, Gocmen H, et al. Which is important in the evaluation of metastatic lymph nodes in head and neck cancer: palpation, ultrasonography, or computed tomography? Otolaryngol Head Neck Surg 2004, 130: 197–201.PubMedCrossRefGoogle Scholar
  33. 33.
    Hao SP, Ng SH. Magnetic resonance imaging versus clinical palpation in evaluating cervical metastasis from head and neck cancer. Otolaryngol Head Neck Surg 2000, 123: 324–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Kau RJ, Alexiou C, Stimmer H, Arnold W. Diagnostic procedures for detection of lymph node metastases in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec 2000, 62: 199–203.PubMedGoogle Scholar
  35. 35.
    Knappe M, Louw M, Gregor RT. Ultrasonography-guided fine-needle aspiration for the assessment of cervical metastases. Arch Otolaryngol Head Neck Surg 2000, 126: 1091–6.PubMedGoogle Scholar
  36. 36.
    Hoft S, Muhle C, Brenner W, et al. Fine-needle aspiration cytology of the sentinel lymph node in head and neck cancer. J Nucl Med 2002, 43: 1585–90.PubMedGoogle Scholar
  37. 37.
    Rottey S, Petrovic M, Bauters W, et al. Evaluation of metastatic lymph nodes in head and neck cancer: a comparative study between palpation, ultrasonography, ultrasound-guided fine needle aspiration cytology and computed tomography. Acta Clin Belg 2006, 61: 236–41.PubMedGoogle Scholar
  38. 38.
    Akoglu E, Dutipek M, Bekis R, et al. Assessment of cervical lymph node metastasis with different imaging methods in patients with head and neck squamous cell carcinoma. J Otolaryngol 2005, 34: 384–94.PubMedCrossRefGoogle Scholar
  39. 39.
    Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003, 134: 946–54; discussion 954–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Eichhorn T, Schroeder HG, Glanz H, Schwerk WB. [Histologically controlled comparison of palpation and sonography in the diagnosis of cervical lymph node metastases]. Laryngol Rhinol Otol (Stuttg) 1987, 66: 266–74.CrossRefGoogle Scholar
  41. 41.
    Steinkamp HJ, Knobber D, Schedel H, et al. [Palpation and sonography in after-care of head-neck tumor patients: comparison of ultrasound tumor entity parameters]. Laryngorhinootologie 1993, 72: 431–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol 1998, 27: 342–7.PubMedGoogle Scholar
  43. 43.
    Takes RP, Righi P, Meeuwis CA, et al. The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. Int J Radiat Oncol Biol Phys 1998, 40: 1027–32.PubMedGoogle Scholar
  44. 44.
    Stokkel MP, ten Broek FW, Hordijk GJ, et al. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emissiontomography. Ann Surg 2000, 231: 229–34.PubMedCrossRefGoogle Scholar
  45. 45.
    Anzai Y, Brunberg JA, Lufkin RB. Imaging of nodal metastases in the head and neck. J Magn Reson Imaging 1997, 7: 774–83.PubMedCrossRefGoogle Scholar
  46. 46.
    Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001, 28: 816–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Salaun P, Abgral R, Querellou S, et al. Does (18) fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck 2007, 29: 1115–20.PubMedCrossRefGoogle Scholar
  48. 48.
    van Overhagen H, Brakel K, Heijenbrok MW, et al. Metastases in supraclavicular lymph nodes in lung cancer: assessment with palpation, US, and CT. Radiology 2004, 232: 75–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Ettinger D, Bepler G, Cox J, et al. Non-small cell lung cancer. NCCN: Practice Guidelines Oncol 2002, 1.Google Scholar
  50. 50.
    Gress FG, Savides TJ, Sandler A, et al. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study. Ann Intern Med 1997, 127: 604–12.PubMedGoogle Scholar
  51. 51.
    Fritscher-Ravens A, Bohuslavizki KH, Brandt L, et al. Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003, 123: 442–51.PubMedCrossRefGoogle Scholar
  52. 52.
    Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006, 130: 710–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003, 348: 2500–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Eloubeidi MA, Cerfolio RJ, Chen VK, et al. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg 2005, 79: 263–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Wallace MB, Silvestri GA, Sahai AV, et al. Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung. Ann Thorac Surg 2001, 72: 1861–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Rintoul RC, Skwarski KM, Murchison JT, et al. Endobronchial and endoscopic ultrasound-guided real-time fine-needle aspiration for mediastinal staging. Eur Respir J 2005, 25: 416–21.PubMedCrossRefGoogle Scholar
  57. 57.
    Wallace MB, Ravenel J, Block MI, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg 2004, 77: 1763–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Reed CE, Mishra G, Sahai AV, et al. Esophageal cancer staging: improved accuracy by endoscopic ultrasound of celiac lymph nodes. Ann Thorac Surg 1999, 67: 319–21; discussion 322.PubMedCrossRefGoogle Scholar
  59. 59.
    Vazquez-Sequeiros E, Wiersema MJ, Clain JE, et al. Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology 2003, 125: 1626–35.PubMedCrossRefGoogle Scholar
  60. 60.
    Kaushik N, Khalid A, Brody D, et al. Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer. Ann Thorac Surg 2007, 83: 2000–2.PubMedCrossRefGoogle Scholar
  61. 61.
    Landmann R, Wong W, Hoepfl J, et al. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum 2007, 50: 1520–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Bianchi P, Ceriani C, Palmisano A, et al. A prospective comparison of endorectal ultrasound and pelvic magnetic resonance in the preoperative staging of rectal cancer. Ann Ital Chir 2006, 77: 41–6.PubMedGoogle Scholar
  63. 63.
    Shami VM, Parmar KS, Waxman I. Clinical impact of endoscopic ultrasound and endoscopic ultrasound-guided fine-needle aspiration in the management of rectal carcinoma. Dis Colon Rectum 2004, 47: 59–65.PubMedCrossRefGoogle Scholar
  64. 64.
    Land R, Herod J, Moskovic E, et al. Routine computerized tomography scanning, groin ultrasound with or without fine needle aspiration cytology in the surgical management of primary squamous cell carcinoma of the vulva. Int J Gynecol Cancer 2006, 16: 312–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Singh K, Orakwue CO, Honest H, et al. Accuracy of magnetic resonance imaging of inguinofemoral lymph nodes in vulval cancer. Int J Gynecol Cancer 2006, 16: 1179–83.PubMedCrossRefGoogle Scholar
  66. 66.
    Artifon EL, Sakai P, Ishioka S, et al. EUS for locoregional staging of prostate cancer – a pilot study. Gastrointest Endosc 2007, 65: 440–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005, 242: 302–11; discussion 311–3.PubMedGoogle Scholar
  68. 68.
    Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007, 25: 3657–63.PubMedCrossRefGoogle Scholar
  69. 69.
    Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17: 976–83.PubMedGoogle Scholar
  70. 70.
    Vanderveen KA, Schneider PD, Khatri VP, et al. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging. Ann Surg Oncol 2006, 13: 1450–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Marrazzo A, Taormina P, Gebbiab V, et al. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients? Chir Ital 2007, 59: 693–9.PubMedGoogle Scholar
  72. 72.
    Wong SL, Chao C, Edwards MJ, et al. The use of cytokeratin staining in sentinel lymph node biopsy for breast cancer. Am J Surg 2001, 182: 330–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127: 392–9.PubMedGoogle Scholar
  74. 74.
    Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999, 230: 453–63; discussion 463–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Cox CE, Bass SS, Boulware D, et al. Implementation of new surgical technology: outcome measures for lymphatic mapping of breast carcinoma. Ann Surg Oncol 1999, 6: 553–61.PubMedCrossRefGoogle Scholar
  76. 76.
    Clarke D, Newcombe RG, Mansel RE. The learning curve in sentinel node biopsy: theALMANAC experience. Ann Surg Oncol 2004, 11: 211S–5S.PubMedGoogle Scholar
  77. 77.
    Kitagawa Y, Kitano S, Kubota T, et al. Minimally invasive surgery for gastric cancer – toward a confluence of two major streams: a review. Gastric Cancer 2005, 8: 103–10.PubMedCrossRefGoogle Scholar
  78. 78.
    Kitajima M, Kitagawa Y. Surgical treatment of esophageal cancer – the advent of the era of individualization. N Engl J Med 2002, 347: 1705–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Faries MB, Bleicher RJ, Ye X, et al. Lymphatic mapping and sentinel lymphadenectomy for primary and metastatic pulmonary malignant neoplasms. Arch Surg 2004, 139: 870–6; discussion 876–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Liptay MJ. Sentinel node mapping in lung cancer. Ann Surg Oncol 2004, 11: 271S–4S.PubMedGoogle Scholar
  81. 81.
    Rzyman W, Hagen OM, Dziadziuszko R, et al. Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients. Ann Thorac Surg 2006, 82: 237–42.PubMedCrossRefGoogle Scholar
  82. 82.
    Muraoka M, Akamine S, Oka T, et al. Sentinel node sampling limits lymphadenectomy in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007, 32: 356–61.PubMedCrossRefGoogle Scholar
  83. 83.
    Cochran AJ, Starz H, Ohsie SJ, et al. Pathologic reporting and special diagnostic techniques for melanoma. Surg Oncol Clin N Am 2006, 15: 231–51.PubMedCrossRefGoogle Scholar
  84. 84.
    Cserni G. Pathological evaluation of sentinel lymph nodes. Surg Oncol Clin N Am 2007, 16: 17–34.PubMedCrossRefGoogle Scholar
  85. 85.
    Turner RR, Nora DT, Trocha SD, Bilchik AJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med 2003, 127: 673–9.PubMedGoogle Scholar
  86. 86.
    Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 2007, 14: 3378–84.PubMedCrossRefGoogle Scholar
  87. 87.
    Grabau D, Jensen MB, Rank F, Blichert-Toft M. Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival. Apmis 2007, 115: 828–37.PubMedCrossRefGoogle Scholar
  88. 88.
    Kuijt GP, Voogd AC, van de Poll-Franse LV, et al. The prognostic significance of axillary lymph-node micrometastases in breast cancer patients. Eur J Surg Oncol 2005, 31: 500–5.PubMedCrossRefGoogle Scholar
  89. 89.
    Scheri RP, Essner R, Turner RR, et al. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 2007, 14: 2861–6.PubMedGoogle Scholar
  90. 90.
    Martinez SR, Mori T, Hoon DS. Molecular upstaging of sentinel lymph nodes in melanoma: where are we now? Surg Oncol Clin N Am 2006, 15: 331–40.PubMedCrossRefGoogle Scholar
  91. 91.
    Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004, 22: 2671–80.PubMedCrossRefGoogle Scholar
  92. 92.
    Gillanders WE, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 2004, 239: 828–37, discussion 837–40.PubMedCrossRefGoogle Scholar
  93. 93.
    Sakaguchi M, Virmani A, Dudak MW, et al. Clinical relevance of reverse transcriptase-polymerase chain reaction for the detection of axillary lymph node metastases in breast cancer. Ann Surg Oncol 2003, 10: 117–25.PubMedCrossRefGoogle Scholar
  94. 94.
    Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol 2006, 13: 1386–92.PubMedCrossRefGoogle Scholar
  95. 95.
    Stojadinovic A, Nissan A, Protic M, et al. Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01. Ann Surg 2007, 245: 846–57.PubMedCrossRefGoogle Scholar
  96. 96.
    Bilchik AJ, Hoon DS, Saha S, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg 2007, 246: 568–75; discussion 575–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg 1999, 230: 692–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Silverstein MJ, Gierson ED, Waisman JR, et al. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg 1995, 180: 700–4.PubMedGoogle Scholar
  99. 99.
    Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997, 79: 1918–22.PubMedCrossRefGoogle Scholar
  100. 100.
    Rivadeneira DE, Simmons RM, Christos PJ, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000, 191: 1–6; discussion 6–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Orucevic A, Reddy VB, Bloom KJ, et al. Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. Breast J 2002, 8: 349–55.PubMedCrossRefGoogle Scholar
  102. 102.
    Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997, 47: 28–51.PubMedCrossRefGoogle Scholar
  103. 103.
    Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer 1993, 71: 2141–50.PubMedCrossRefGoogle Scholar
  104. 104.
    Tsang RW, Juvet S, Pintilie M, et al. Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy. Clin Cancer Res 2003, 9: 4387–95.PubMedGoogle Scholar
  105. 105.
    Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994, 10: 31–46.PubMedCrossRefGoogle Scholar
  106. 106.
    Sakuragi N, Takeda N, Hareyama H, et al. A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph node metastases in patients with cervical carcinoma. Cancer 2000, 88: 2578–83.PubMedCrossRefGoogle Scholar
  107. 107.
    Merkel S, Mansmann U, Papadopoulos T, et al. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer 2001, 92: 2754–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Haupt B, Ro JY, Schwartz MR, Shen SS. Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis. Mod Pathol 2007, 20: 729–33.PubMedCrossRefGoogle Scholar
  109. 109.
    Artinyan A, Essani R, Lake J, et al. Molecular predictors of lymph node metastasis in colon cancer: increased risk with decreased thymidylate synthase expression. J Gastrointest Surg 2005, 9: 1216–21; discussion 1221.PubMedCrossRefGoogle Scholar
  110. 110.
    Kalogiannidis I, Lambrechts S, Amant F, et al. Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients. Int J Gynecol Cancer 2006, 16: 1885–93.PubMedCrossRefGoogle Scholar
  111. 111.
    Kamura T, Yahata H, Shigematsu T, et al. Predicting pelvic lymph node metastasis in endometrial carcinoma. Gynecol Oncol 1999, 72: 387–91.PubMedCrossRefGoogle Scholar
  112. 112.
    Cheewakriangkrai C, Panggid K, Siriaungkul S, et al. Lymphovascular space invasion as a prognostic determinant in uterine cancer. Asian Pac J Cancer Prev 2007, 8: 363–6.PubMedGoogle Scholar
  113. 113.
    Tang X, Tanemura K, Ye W, et al. Clinicopathological factors predicting retroperitoneal lymph node metastasis and survival in endometrial cancer. Jpn J Clin Oncol 1998, 28: 673–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Nomura H, Aoki D, Suzuki N, et al. Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer. Int J Gynecol Cancer 2006, 16: 799–804.PubMedCrossRefGoogle Scholar
  115. 115.
    Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001, 6: 47–86.PubMedGoogle Scholar
  116. 116.
    Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005, 242: 566–73; discussion 573–5.PubMedGoogle Scholar
  117. 117.
    Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003, 97: 2995–3002.PubMedCrossRefGoogle Scholar
  118. 118.
    Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001, 166: 68–72.PubMedCrossRefGoogle Scholar
  119. 119.
    Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004, 172: 465–9.PubMedCrossRefGoogle Scholar
  120. 120.
    Hutterer GC, Patard JJ, Jeldres C, et al. Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram. BJU Int 2008, 101: 39–43.PubMedCrossRefGoogle Scholar
  121. 121.
    Ward JF, Blute ML, Cheville JC, et al. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol 2002, 168: 56–60.PubMedCrossRefGoogle Scholar
  122. 122.
    Almadori G, Bussu F, Paludettii G. Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification. Acta Otorhinolaryngol Ital 2006, 26: 326–34.PubMedGoogle Scholar
  123. 123.
    Wolf GT, Fisher SG, Truelson JM, Beals TF. DNA content and regional metastases in patients with advanced laryngeal squamous carcinoma. Department of Veterans Affairs Laryngeal Study Group. Laryngoscope 1994, 104: 479–83.PubMedGoogle Scholar
  124. 124.
    Franchi A, Gallo O, Boddi V, Santucci M. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination. Clin Cancer Res 1996, 2: 1801–8.PubMedGoogle Scholar
  125. 125.
    Schipper JH, Unger A, Jahnke K. E-cadherin as a functional marker of the differentiation and invasiveness of squamous cell carcinoma of the head and neck. Clin Otolaryngol Allied Sci 1994, 19: 381–4.PubMedCrossRefGoogle Scholar
  126. 126.
    Myo K, Uzawa N, Miyamoto R, et al. Cyclin D1 gene numerical aberration is a predictive marker for occult cervical lymph node metastasis in TNM Stage I and II squamous cell carcinoma of the oral cavity. Cancer 2005, 104: 2709–16.PubMedCrossRefGoogle Scholar
  127. 127.
    Civantos F, Zitsch R, Bared A. Sentinel node biopsy in oral squamous cell carcinoma. J Surg Oncol 2007, 96: 330–6.PubMedCrossRefGoogle Scholar
  128. 128.
    Kowalski LP, Bagietto R, Lara JR, et al. Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck 2000, 22: 207–14.PubMedCrossRefGoogle Scholar
  129. 129.
    Moe K, Wolf GT, Fisher SG, Hong WK. Regional metastases in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1996, 122: 644–8.PubMedGoogle Scholar
  130. 130.
    Sun HC, Zhuang PY, Qin LX, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 2007, 96: 37–45.PubMedCrossRefGoogle Scholar
  131. 131.
    Sotiropoulos GC, Malago M, Molmenti EP, et al. Hilar lymph nodes sampling at the time of liver transplantation for hepatocellular carcinoma: to do or not to do? Meta-analysis to determine the impact of hilar lymph nodes metastases on tumor recurrence and survival in patients with hepatocellular carcinoma undergoing liver transplantation. Transpl Int 2007, 20: 141–6.PubMedCrossRefGoogle Scholar
  132. 132.
    Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998, 228: 479–90.PubMedCrossRefGoogle Scholar
  133. 133.
    Boerma EJ. Towards an oncological resection of gall bladder cancer. Eur J Surg Oncol 1994, 20: 537–44.PubMedGoogle Scholar
  134. 134.
    Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg 2007, 11: 1478–86; discussion 1486–7.PubMedCrossRefGoogle Scholar
  135. 135.
    Shirabe K, Shimada M, Harimoto N, et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery 2002, 131: S159–64.PubMedCrossRefGoogle Scholar
  136. 136.
    Kokudo N, Makuuchi M. Extent of resection and outcome after curative resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2002, 11: 969–83.PubMedCrossRefGoogle Scholar
  137. 137.
    Yamamoto M, Takasaki K, Yoshikawa T. Lymph node metastasis in intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 1999, 29: 147–50.PubMedCrossRefGoogle Scholar
  138. 138.
    Murakami Y, Uemura K, Hayashidani Y, et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol 2007, 95: 207–12.PubMedCrossRefGoogle Scholar
  139. 139.
    Shafazand S, Gould MK. A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer. J Thorac Oncol 2006, 1: 953–9.PubMedCrossRefGoogle Scholar
  140. 140.
    Sawyer TE, Bonner JA, Gould PM, et al. Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: implications in the inoperable and three-dimensional dose-escalation settings. Int J Radiat Oncol Biol Phys 1999, 43: 965–70.PubMedCrossRefGoogle Scholar
  141. 141.
    Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg 2008, 85: 211–5.PubMedCrossRefGoogle Scholar
  142. 142.
    Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007, 109: 100–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007, 25:869–75.PubMedCrossRefGoogle Scholar
  144. 144.
    Cochran AJ, Huang RR, Lee J, et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006, 6: 659–70.PubMedCrossRefGoogle Scholar
  145. 145.
    Karakousis GC, Gimotty PA, Czerniecki BJ, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Ann Surg Oncol 2007, 14: 1596–603.PubMedCrossRefGoogle Scholar
  146. 146.
    Balch C, Soong S, Atkins M, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004, 54: 131–49.PubMedCrossRefGoogle Scholar
  147. 147.
    Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 2006, 103: 797–801.PubMedCrossRefGoogle Scholar
  148. 148.
    Ushijima K. Management of retroperitoneal lymph nodes in the treatment of ovarian cancer. Int J Clin Oncol 2007, 12: 181–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003, 197: 198–205.PubMedCrossRefGoogle Scholar
  150. 150.
    Takeshima N, Hirai Y, Umayahara K, et al. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol 2005, 99: 427–31.PubMedCrossRefGoogle Scholar
  151. 151.
    Onda T, Yoshikawa H, Yasugi T, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer 1998, 83: 1555–60.PubMedCrossRefGoogle Scholar
  152. 152.
    Suzuki M, Ohwada M, Yamada T, et al. Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol 2000, 79: 305–8.PubMedCrossRefGoogle Scholar
  153. 153.
    Eisenkop SM, Spirtos NM. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol 2001, 82: 143–9.PubMedCrossRefGoogle Scholar
  154. 154.
    Spirtos NM, Gross GM, Freddo JL, Ballon SC. Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 1995, 56: 345–52.PubMedCrossRefGoogle Scholar
  155. 155.
    Nakagohri T, Kinoshita T, Konishi M, et al. Nodal involvement is strongest predictor of poor survival in patients with invasive adenocarcinoma of the head of the pancreas. Hepatogastroenterology 2006, 53: 447–51.PubMedGoogle Scholar
  156. 156.
    House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007, 11: 1549–55.PubMedCrossRefGoogle Scholar
  157. 157.
    Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141: 610–8.PubMedCrossRefGoogle Scholar
  158. 158.
    Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4: 567–79.PubMedCrossRefGoogle Scholar
  159. 159.
    Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 2007, 142: 767–723; discussion 773–4.PubMedCrossRefGoogle Scholar
  160. 160.
    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003, 169: 849–54.PubMedCrossRefGoogle Scholar
  161. 161.
    Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003, 170: 1798–803.PubMedCrossRefGoogle Scholar
  162. 162.
    Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277: 1445–51.PubMedCrossRefGoogle Scholar
  163. 163.
    Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006, 49: 1019–26; discussion 1026–7.PubMedCrossRefGoogle Scholar
  164. 164.
    Briganti A, Shariat SF, Chun FK, et al. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. BJU Int 2007, 100: 528–32.PubMedCrossRefGoogle Scholar
  165. 165.
    Cheng L, Bergstralh EJ, Cheville JC, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998, 22: 1491–500.PubMedCrossRefGoogle Scholar
  166. 166.
    Daneshmand S, Quek ML, Stein JP, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004, 172: 2252–5.PubMedCrossRefGoogle Scholar
  167. 167.
    Scher H, Leibel S, Fuks Z, et al. Cancer of the postate. In: Cancer: Principles and Practice of Oncology (DeVita V, Hellman S, Rosenberg S, Eds.), pp. 1192–1259. Lippincott Williams & Wilkins, Philadelphia, 2005.Google Scholar
  168. 168.
    Yokota T, Ishiyama S, Saito T, et al. Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol 2004, 39: 380–4.PubMedCrossRefGoogle Scholar
  169. 169.
    Folli S, Morgagni P, Roviello F, et al. Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 2001, 31: 495–9.PubMedCrossRefGoogle Scholar
  170. 170.
    Nasu J, Nishina T, Hirasaki S, et al. Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers. J Clin Gastroenterol 2006, 40: 412–5.PubMedCrossRefGoogle Scholar
  171. 171.
    An JY, Baik YH, Choi MG, et al. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Ann Surg 2007, 246: 749–53.PubMedCrossRefGoogle Scholar
  172. 172.
    Abe N, Watanabe T, Suzuki K, et al. Risk factors predictive of lymph node metastasis in depressed early gastric cancer. Am J Surg 2002, 183: 168–72.PubMedCrossRefGoogle Scholar
  173. 173.
    Kunisaki C, Shimada H, Nomura M, Akiyama H. Appropriate lymph node dissection for early gastric cancer based on lymph node metastases. Surgery 2001, 129: 153–7.PubMedCrossRefGoogle Scholar
  174. 174.
    Abe N, Sugiyama M, Masaki T, et al. Predictive factors for lymph node metastasis of differentiated submucosally invasive gastric cancer. Gastrointest Endosc 2004, 60: 242–5.PubMedCrossRefGoogle Scholar
  175. 175.
    Borie F, Millat B, Fingerhut A, et al. Lymphatic involvement in early gastric cancer: prevalence and prognosis in France. Arch Surg 2000, 135: 1218–23.PubMedCrossRefGoogle Scholar
  176. 176.
    Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation Study. Cancer 2000, 89: 202–17.PubMedCrossRefGoogle Scholar
  177. 177.
    Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003, 237: 399–407.PubMedCrossRefGoogle Scholar
  178. 178.
    Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993, 217: 72–7.PubMedCrossRefGoogle Scholar
  179. 179.
    Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 2004, 426: 129–34.PubMedCrossRefGoogle Scholar
  180. 180.
    Ariel IM. Incidence of metastases to lymph nodes from soft-tissue sarcomas. Semin Surg Oncol 1988, 4: 27–9.PubMedCrossRefGoogle Scholar
  181. 181.
    Gaakeer HA, Albus-Lutter CE, Gortzak E, Zoetmulder FA. Regional lymph node metastases in patients with soft tissue sarcomas of the extremities, what are the therapeutic consequences? Eur J Surg Oncol 1988, 14: 151–6.PubMedGoogle Scholar
  182. 182.
    Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987, 60: 1800–8.PubMedCrossRefGoogle Scholar
  183. 183.
    Caceres E, Zaharia M, Calderon R. Incidence of regional lymph node metastasis in operable osteogenic sarcoma. Semin Surg Oncol 1990, 6: 231–3.PubMedCrossRefGoogle Scholar
  184. 184.
    Blazer DG, 3rd, Sabel MS, Sondak VK. Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surg Oncol 2003, 12: 201–6.PubMedCrossRefGoogle Scholar
  185. 185.
    Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006, 244: 602–10.PubMedGoogle Scholar
  186. 186.
    Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005, 97: 219–25.PubMedGoogle Scholar
  187. 187.
    Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970, 131: 79–88.PubMedGoogle Scholar
  188. 188.
    Blancas I, Garcia-Puche JL, Bermejo B, et al. Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. Ann Oncol 2006, 17: 1644–9.PubMedCrossRefGoogle Scholar
  189. 189.
    Pieterse QD, Kenter GG, Gaarenstroom KN, et al. The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancer. Eur J Surg Oncol 2007, 33: 216–21.PubMedCrossRefGoogle Scholar
  190. 190.
    Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002, 167: 1295–8.PubMedCrossRefGoogle Scholar
  191. 191.
    Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008, 15: 165–74.PubMedCrossRefGoogle Scholar
  192. 192.
    Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 2006, 13: 1189–200.PubMedCrossRefGoogle Scholar
  193. 193.
    Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 2008, Mar 15, 112: 1239–46.PubMedCrossRefGoogle Scholar
  194. 194.
    Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008, 247: 365–71.PubMedCrossRefGoogle Scholar
  195. 195.
    Shen JY, Kim S, Cheong JH, et al. The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancer. Cancer 2007, 110: 745–51.PubMedCrossRefGoogle Scholar
  196. 196.
    Benson AB, 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22: 3408–19.PubMedCrossRefGoogle Scholar
  197. 197.
    Iyer RV, Hanlon A, Fowble B, et al. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys 2000, 47: 1177–83.PubMedGoogle Scholar
  198. 198.
    Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347: 567–75.PubMedCrossRefGoogle Scholar
  199. 199.
    Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366: 2087–106.PubMedGoogle Scholar
  200. 200.
    Kato H, Watanabe H, Tachimori Y, Iizuka T. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg 1991, 51: 931–5.PubMedCrossRefGoogle Scholar
  201. 201.
    Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998, 175: 47–51.PubMedCrossRefGoogle Scholar
  202. 202.
    Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347: 1662–9.PubMedCrossRefGoogle Scholar
  203. 203.
    Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007, 246: 992–1000; discussion 1000–1.PubMedCrossRefGoogle Scholar
  204. 204.
    Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.J Clin Oncol 2004, 22: 2069–77.PubMedCrossRefGoogle Scholar
  205. 205.
    Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005, 138: 618–28; discussion 628–30.PubMedCrossRefGoogle Scholar
  206. 206.
    Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999, 229: 613–22; discussion 622–4.PubMedCrossRefGoogle Scholar
  207. 207.
    Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005, 92: 547–56.PubMedCrossRefGoogle Scholar
  208. 208.
    Havenga K, Enker WE, Norstein J, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 1999, 25: 368–74.PubMedCrossRefGoogle Scholar
  209. 209.
    Mortenson MM, Khatri VP, Bennett JJ, Petrelli NJ. Total mesorectal excision and pelvic node dissection for rectal cancer: an appraisal. Surg Oncol Clin N Am 2007, 16: 177–97.PubMedCrossRefGoogle Scholar
  210. 210.
    Balch C, Soong S, Ross M, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas(1.0–4.0 mm). Ann Surg Oncol 2000, 7: 87–97.PubMedCrossRefGoogle Scholar
  211. 211.
    Ung YC, Maziak DE, Vanderveen JA, et al. 18 Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007, 99: 1753–67.PubMedCrossRefGoogle Scholar
  212. 212.
    Dam HQ, Manzone TM, Sagar VV. Evolving role of 18F-Fluorodeoxyglucose in the management of esophageal carcinoma. Surg Oncol Clin N Am 2006, 15: 733–49.PubMedCrossRefGoogle Scholar
  213. 213.
    Myenberger C, Huch Boni RI, Bertschinger P, Zala GF, Klotz HP, Krestin GP. Endoscopic ultrasound and endorectal magnetic resonance imaging: a prospective, comparative study for preoperative staging and follow-up of rectal cancer. Endoscopy 1995, 27: 469–79.CrossRefGoogle Scholar
  214. 214.
    Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel nodes in melanoma patients. J Clin Oncol 2004, 22:2671–80.PubMedCrossRefGoogle Scholar
  215. 215.
    Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005, 242: 566–73.PubMedGoogle Scholar
  216. 216.
    Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987; 5: 1378.PubMedGoogle Scholar
  217. 217.
    Noguchi M, Minami M, Earashi M, Taniya T, Miyazaki I, Mizukami Y, Nonomura A. Intraoperative histologic assessment of surgical margins and lymph node metastasis in breast-conserving surgery. Arch Surg 1993, 128: 242.PubMedGoogle Scholar
  218. 218.
    Axelsson K, Ljung BME, Moore DH II, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995, 87: 997–1008.PubMedCrossRefGoogle Scholar
  219. 219.
    Meyer JS, Province M. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 1988 Oct, 12: 191–204.PubMedCrossRefGoogle Scholar
  220. 220.
    Fisher B, Fisher ER, Redmond C, et al. Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res Treat 1986, 7: 147.PubMedCrossRefGoogle Scholar
  221. 221.
    Shek LL, Godolphin W: Survival with breast cancer: the importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 1989, 25: 243–50.PubMedCrossRefGoogle Scholar
  222. 222.
    Meyer JS, Province MA. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer. 1994 Oct 15, 74: 2287–2299.PubMedCrossRefGoogle Scholar
  223. 223.
    Wenger CR, Beardslee S, Owens MA, Pounds S, Oldaker T, Vendely P, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993, 28: 9–20.PubMedCrossRefGoogle Scholar
  224. 224.
    Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993, 71: 2006–12.PubMedCrossRefGoogle Scholar
  225. 225.
    National Institutes of Health Consensus, Development Conference Statement. June 18–21, 1990, 8(6).Google Scholar
  226. 226.
    Duffy MJ, Reilly D, McDermott E, O’Higgins N, Fennally JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994, 74: 2276–80.PubMedCrossRefGoogle Scholar
  227. 227.
    Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast carcinoma. Cancer. 1994 Jul 1, 74: 381–400.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Division of Surgical Oncology, The Roy E. Coats Research LaboratoriesJohn Wayne Cancer Institute, Saint John’s Health CenterSanta MonicaUSA

Personalised recommendations